PZKKN-94 is a dual serotonin 5-HT1B receptor agonist and serotonin 5-HT6 receptor antagonist which is under investigation for the potential treatment of Parkinson's disease.[1] Its values were 39 nM (EC50Tooltip half-maximal effective concentration) and 88.1% (EmaxTooltip maximal efficacy) at the serotonin 5-HT1B receptor and 7.7 nM (KB) at the serotonin 5-HT6 receptor.[1] The drug showed selectivity for these receptors over 43 other targets.[1] It shows favorable drug-like properties.[1] In rodents, PZKKN-94 shows antiparkinsonian-like, pro-cognitive, and antidepressant-like effects.[1] PZKNN-94 was first described in the scientific literature by Paweł Zajdel and colleagues in 2025.[1]

See also

References

  1. 1 2 3 4 5 6
source: https://en.wikipedia.org/wiki/PZKKN-94